After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Fate Therapeutics Inc is $695.67M. A total of 2.64 million shares were traded on the day, compared to an average of 2.94M shares.
In the most recent transaction, Dulac Edward J III sold 2,447 shares of FATE for 7.77 per share on Mar 04 ’24. After the transaction, the Chief Financial Officer now owns 101,479 company shares. In a previous transaction on Jan 29 ’24, Dulac Edward J III sold 1,849 shares at 5.00 per share. FATE shares that Chief Financial Officer owns now total 103,926.
Among the insiders who sold shares, Wolchko J Scott disposed of 14,391 shares on Jan 09 ’24 at a per-share price of $4.37. This resulted in the President and CEO holding 371,248 shares of FATE after the transaction. In another insider transaction, Valamehr Bahram sold 11,271 shares at $4.38 per share on Jan 09 ’24. Company shares held by the Chief R&D Officer now total 158,069.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, FATE has a high of $8.83 and a low of $1.63.
As of this writing, FATE has an earnings estimate of -$0.49 per share for the current quarter. EPS was calculated based on a consensus of 18 estimates, with a high estimate of -$0.43 per share and a lower estimate of -$0.67. The company reported an EPS of -$0.46 in the last quarter, which was 19.30% higher than expectations of -$0.57.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. FATE’s latest balance sheet shows that the firm has $615.91M in Cash & Short Term Investments as of fiscal 2021. There were $114.82M in debt and $81.28M in liabilities at the time. Its Book Value Per Share was $3.74, while its Total Shareholder’s Equity was $678.84M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FATE is Buy with a score of 3.43.
